Haleon PLC Sponsored ADR $HLN Shares Sold by Cambiar Investors LLC

Cambiar Investors LLC decreased its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 94.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 66,003 shares of the company’s stock after selling 1,229,351 shares during the period. Cambiar Investors LLC’s holdings in Haleon were worth $592,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. Brighton Jones LLC acquired a new stake in Haleon in the 4th quarter valued at approximately $187,000. AQR Capital Management LLC increased its holdings in shares of Haleon by 22.5% during the first quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock valued at $991,000 after purchasing an additional 17,720 shares during the period. Focus Partners Wealth raised its stake in shares of Haleon by 7.6% during the first quarter. Focus Partners Wealth now owns 73,106 shares of the company’s stock valued at $752,000 after purchasing an additional 5,178 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after purchasing an additional 1,203 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its position in Haleon by 10.8% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 104,940 shares of the company’s stock valued at $1,076,000 after buying an additional 10,192 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

HLN has been the topic of a number of recent analyst reports. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Jefferies Financial Group reissued a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Hsbc Global Res upgraded Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a research report on Monday, January 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Haleon presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.32 on Thursday. The company has a market capitalization of $45.94 billion, a PE ratio of 26.45 and a beta of 0.19. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.63 and a current ratio of 0.87. The stock has a fifty day moving average of $9.90 and a 200-day moving average of $9.61. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.